Company & Sponsor Intelligence

Genentech, Inc.

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials8

Recruiting0

Completed7

Countries1

Therapeutic footprint

alzheimersmultiple_sclerosisneuromuscularstroke

Indexed studies

NCT04377555Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab
multiple_sclerosis · United StatesPHASE4

NCT05232929Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)
neuromuscular · United StatesPHASE4

NCT02820896A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease
alzheimers · United StatesPHASE1

NCT03785678Tenecteplase in Stroke Patients Between 4.5 and 24 Hours
stroke · United StatesPHASE3

NCT02637856A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
multiple_sclerosis · United StatesPHASE3

NCT01343966A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
alzheimers · United StatesPHASE2

NCT01723826A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
alzheimers · United StatesPHASE2

NCT03289143A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease
alzheimers · United StatesPHASE2

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →